Transaction overview
Shannon Lei Okinaka, who serves on the board of Universal Technical Institute (NYSE:UTI), completed the sale of 10,000 shares of the company’s common stock on March 6, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The proceeds from the transaction totaled approximately $347,414, with the executed prices per share ranging from $34.54 to $35.3456.
Shareholding after sale
Following the disposition, Okinaka is listed as directly owning 19,808 shares of Universal Technical Institute. At the time of reporting, the market price for UTI was $35.17, reflecting a 34.6% gain year-to-date and a 29.5% increase over the last six months.
Valuation context cited
InvestingPro analysis referenced in the filing notes that UTI is trading above its Fair Value estimate. That assessment is cited as potential context for the director’s decision to sell shares. The company is also included among the more than 1,400 U.S. equities covered by InvestingPro’s Pro Research Reports.
Recent operating results
Universal Technical Institute reported first-quarter results for fiscal 2026 that were mixed against expectations. The company posted earnings per share of $0.23, narrowly missing the consensus forecast of $0.24, a 4.17% negative surprise. Revenue for the quarter came in at $220.8 million, outperforming the projected $216.81 million.
Analyst stance
Truist Securities has reiterated its Buy rating on Universal Technical Institute and maintained a price target of $40.00. In its commentary, Truist highlighted that student enrollment starts are expected to accelerate through the remainder of the year, a factor it flagged as supportive of the company’s growth outlook.
What the filing shows
The Form 4 provides the transaction date, price range per share, total shares sold, and the resulting direct ownership figure for Okinaka. Those elements together document the director-level sale against the backdrop of recent operating performance and analyst commentary.
Note: The article presents filing details, reported quarterly results, and analyst guidance as disclosed in public documents and research notes.